(Total Views: 436)
Posted On: 09/16/2019 1:08:20 PM
Post# of 1460
There is a reason behind the price going up......below from IHUB falconer66a,
Fletch
falconer66a Monday, 09/16/19 01:02:33 PM
Re: None 0
Post # of 209962
Just the First
Today’s announcement of positive clinical results in adults with Rett syndrome, being treated with but 5mg of Anavex 2-73, is just the first. Each of the other clinical trials will likewise reveal Anavex 2-73 efficacies for the central nervous system diseases in each: Parkinson’s Disease Dementia, and Alzheimer’s Disease; for these crucial reasons.
Yes, Anavex 2-73 successfully treated mice with Rett syndrome traits: “The data demonstrates dose related and significant improvements in an array of behavioral and gait paradigms in a mouse model with a MECP2-null mutation that causes neurological symptoms that mimic Rett syndrome.” https://www.biospace.com/article/releases/ana...syndrome-/
And, now, it is reported that adult humans with Rett, likewise, experienced symptomatic improvements when taking the drug. Anavex 2-73 worked well in mice. Now, it works in adult humans, too. Same drug. Same mechanism of action in both species. Same results.
This is important. Treatment of adults with Rett would be far more difficult than treatment in infants or children with the disease. By adulthood, nerves have been chronically disrupted, their biochemical anomalies rather burned in. Rett is a seriously progressing disease; older is worser. If Anavex 2-73 brings levels of relief to these ladies, it will almost certainly be even more effective when administered to little girls with the disease.
Simply, Anavex 2-73 successfully treated not only mice with Rett syndrome genetics, but mice with Parkinson’s and Alzheimer’s symptoms, too. Same thing will happen with humans with these diseases. Sooner or later, positive clinical results will appear from those two Anavex trials. Not a single reason that either of these could fail. Beating Rett, a very serious, lethal genetic/chromosome debility, is harder than either Parkinson’s or Alzheimer’s.
Anavex wins (as will the millions of patients living more normal lives taking Anavex sigma-1 receptor agonists).
Next will be Anavex 3-71. Results there will be even more astonishing.
https://investorshub.advfn.com/boards/read_ms...=151161945
Fletch
falconer66a Monday, 09/16/19 01:02:33 PM
Re: None 0
Post # of 209962
Just the First
Today’s announcement of positive clinical results in adults with Rett syndrome, being treated with but 5mg of Anavex 2-73, is just the first. Each of the other clinical trials will likewise reveal Anavex 2-73 efficacies for the central nervous system diseases in each: Parkinson’s Disease Dementia, and Alzheimer’s Disease; for these crucial reasons.
Yes, Anavex 2-73 successfully treated mice with Rett syndrome traits: “The data demonstrates dose related and significant improvements in an array of behavioral and gait paradigms in a mouse model with a MECP2-null mutation that causes neurological symptoms that mimic Rett syndrome.” https://www.biospace.com/article/releases/ana...syndrome-/
And, now, it is reported that adult humans with Rett, likewise, experienced symptomatic improvements when taking the drug. Anavex 2-73 worked well in mice. Now, it works in adult humans, too. Same drug. Same mechanism of action in both species. Same results.
This is important. Treatment of adults with Rett would be far more difficult than treatment in infants or children with the disease. By adulthood, nerves have been chronically disrupted, their biochemical anomalies rather burned in. Rett is a seriously progressing disease; older is worser. If Anavex 2-73 brings levels of relief to these ladies, it will almost certainly be even more effective when administered to little girls with the disease.
Simply, Anavex 2-73 successfully treated not only mice with Rett syndrome genetics, but mice with Parkinson’s and Alzheimer’s symptoms, too. Same thing will happen with humans with these diseases. Sooner or later, positive clinical results will appear from those two Anavex trials. Not a single reason that either of these could fail. Beating Rett, a very serious, lethal genetic/chromosome debility, is harder than either Parkinson’s or Alzheimer’s.
Anavex wins (as will the millions of patients living more normal lives taking Anavex sigma-1 receptor agonists).
Next will be Anavex 3-71. Results there will be even more astonishing.
https://investorshub.advfn.com/boards/read_ms...=151161945
(2)
(0)Scroll down for more posts ▼
